- Intensity-modulated radiation therapy in early stage squamous cell carcinoma of the larynx: treatment trends and outcomes
-
Wegner RE, Abel S, Bergin JJ, Colonias A
- KMID: 2501448
- Radiat Oncol J.
- 2020 Mar;38(1):11-17.
- doi: 10.3857/roj.2019.00619
Purpose: Definitive radiotherapy remains a primary treatment option for early stage glottic cancer. Intensity-modulated radiation therapy (IMRT) has emerged as the standard treatment technique for advanced head and neck cancers,... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends in the use of radiation for meningioma across the United States
-
Matani H, Abel S, Yu A, Karlovits SM, Wegner RE
- KMID: 2527626
- Radiat Oncol J.
- 2022 Mar;40(1):29-36.
- doi: 10.3857/roj.2021.00563
Purpose: Meningiomas are tumors originating from arachnoid cap cells on the surface of the brain or spinal cord. Treatment differs by grade but can consist of observation, surgery, radiation therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends in intensity-modulated radiation therapy use for rectal cancer in the neoadjuvant setting: a National Cancer Database analysis
-
Wegner RE, Abel S, White RJ, Horne ZD, Hasan S, Kirichenko AV
- KMID: 2434316
- Radiat Oncol J.
- 2018 Dec;36(4):276-284.
- doi: 10.3857/roj.2018.00465
PURPOSE: Traditionally, three-dimensional conformal radiation therapy (3D-CRT) is used for neoadjuvant chemoradiation in locally advanced rectal cancer. Intensity-modulated radiation therapy (IMRT) was later developed for more conformal dose distribution, with... -
- CITED
-
- Close
- SHARE
-
- Close
- National trends in radiation dose escalation for glioblastoma
-
Wegner RE, Abel S, Horne ZD, Hasan S, Verma V, Ranjan T, Williamson RW, Karlovits
- KMID: 2447547
- Radiat Oncol J.
- 2019 Mar;37(1):13-21.
- doi: 10.3857/roj.2019.00017
PURPOSE: Glioblastoma (GBM) carries a high propensity for in-field failure despite trimodality management. Past studies have failed to show outcome improvements with dose-escalation. Herein, we examined trends and outcomes associated... -
- CITED
-
- Close
- SHARE
-
- Close
